Stocks · News reference

Leerink Partners Maintains Market Perform on Dentsply Sirona, Lowers Price Target to $10

Oct 14, 2026, 8:42 PMBenzinga Newsdesk

Leerink Partners analyst Michael Cherny maintains Dentsply Sirona (NASDAQ:XRAY) with a Market Perform and lowers the price target from $14 to $10.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGAROct 9, 2026, 8:16 PMSEC EDGAR
8-K filing — DENTSPLY SIRONA Inc. (XRAY)
Filed: 2026-10-09 AccNo: 0000818479-26-000278 Size: 152 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits
XRAY
BenzingaOct 9, 2026, 5:16 PMBenzinga Newsdesk
Piper Sandler Maintains Neutral on Dentsply Sirona, Lowers Price Target to $12
XRAY
BenzingaOct 7, 2026, 12:38 PMBenzinga Newsdesk
Dentsply Sirona Unit Wellspect HealthCare Announces That Its Surity Urinary Management Portfolio May Be Covered By Traditional Medicare For Eligible Beneficiaries When Medically Necessary
This milestone represents an important step in expanding access and reducing barriers to at-home management for people affected by severe urinary incontinence in the U.S. The Surity™ portfolio provides non-invasive
XRAY